Infectious Disease Clinical Trials Update: Week 32, 2026

Published August 7, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Azithromycin for Child Survival in Niger: Mortality and Resistance Trial

This Phase 4 trial tested giving azithromycin to children under five years old in Niger every six months. The goal was to see if this approach could lower death rates while avoiding increased antibiotic resistance. The study is now complete, and its results could help guide safer use of antibiotics to save young children’s lives in areas with high infection risks.

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds

This Phase 3 study tested a new vaccine aimed at protecting children and teenagers from meningococcal meningitis, a serious bacterial infection. Conducted in China with 840 participants, the trial focused on a vaccine covering multiple meningococcal groups. Results are awaited and could provide an additional way to prevent this dangerous illness for school-aged children.

WiseApp for Spanish Speakers Living With HIV

This study explored the use of a mobile app combined with a smart pill dispenser to help Spanish-speaking people living with HIV take their medications more consistently. Conducted in the US and the Dominican Republic with 241 participants, the trial aimed to improve HIV treatment adherence by using technology tailored to language and culture. The findings will help develop better support tools for managing HIV.

A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years

This Phase 3 trial tested a meningococcal vaccine in adults to evaluate how well it triggers an immune response and its safety. With 1480 participants in Indonesia, the study may lead to more vaccine options for preventing meningococcal meningitis in adults, a serious and potentially life-threatening infection. Results are still pending.

Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection RSV in Children Under 6 Months in Bogotá

This study is looking at two ways to protect babies younger than six months from severe infections caused by the respiratory syncytial virus, or RSV. Taking place in Bogotá, Colombia, it is testing vaccinations given to mothers and newborns to reduce hospital stays and serious illness in very young infants. This research could improve protection strategies for vulnerable babies.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.